Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

156.76
+2.731.77%
Post-market: 158.531.77+1.13%17:43 EDT
Volume:878.42K
Turnover:137.12M
Market Cap:15.99B
PE:22.98
High:157.03
Open:154.31
Low:153.70
Close:154.03
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:0.81
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.33
PE(LYR):33.57

Loading ...

J.P. Morgan Keeps Their Buy Rating on Neurocrine (NBIX)

TIPRANKS
·
May 06

Neurocrine (NBIX) Gets a Buy from Piper Sandler

TIPRANKS
·
May 06

Neurocrine (NBIX) Receives a Buy from Guggenheim

TIPRANKS
·
May 06

Neurocrine Biosciences Inc : Morgan Stanley Raises Target Price to $191.00 From $185.00

THOMSON REUTERS
·
May 06

Neurocrine Biosciences Inc : Citigroup Raises Target Price to $246 From $242

THOMSON REUTERS
·
May 06

Neurocrine Biosciences Inc : Piper Sandler Raises Target Price to $207 From $190

THOMSON REUTERS
·
May 06

Neurocrine Biosciences Delivers Record Quarter, Eyes 2027

TIPRANKS
·
May 06

Ami Fadia Reiterates Buy on NBIX After Strong 1Q26 Beat and Robust Ingrezza and Crenessity Demand

TIPRANKS
·
May 06

Neurocrine Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating

TIPRANKS
·
May 06

Stock Track | Neurocrine Biosciences Soars 8.85% After-Hours on Strong Q1 Earnings Beat and $2.9B Acquisition

Stock Track
·
May 06

Neurocrine Biosciences Q1 adjusted EPS beats estimates, sales up 44%

Reuters
·
May 06

Neurocrine reports Q1 adjusted EPS $1.94, consensus $1.70

TIPRANKS
·
May 06

Neurocrine backs FY26 Ingrezza net product sales $2.7B-$2.8B

TIPRANKS
·
May 06

Neurocrine Q1 FY26 net income rises to $197.9 million; net product sales climb 44% to $811 million

Reuters
·
May 06

BRIEF-Neurocrine Biosciences Q1 Adjusted EPS USD 1.94 Vs. IBES Estimate USD 1.15

Reuters
·
May 06

Neurocrine Biosciences Q1 Net Income USD 197.9 Million

THOMSON REUTERS
·
May 06

Neurocrine Biosciences Inc - Reaffirms 2026 Full-Year Ingrezza Net Sales Guidance $2.7-$2.8 Bln

THOMSON REUTERS
·
May 06

Neurocrine Biosciences executives to present at Bank of America Health Care Conference

Reuters
·
May 05

BRIEF-Neurocrine Biosciences Announces New Survey Results Showing Significant Burden Of Tardive Dyskinesia On Employment

Reuters
·
May 04